Articles On Immuron (ASX:IMC)

Australian company Immuron (ASX:IMC) has updated investors on the impact of COVID-19 and announced the resignation of its CEO.

It’s an all-out bloodbath taking place on the ASX today. But amid the carnage, a few small-caps still posted gains as a flurry of half-year results hit the market. Leading the way was $16m telecommunications company United Networks (ASX:UNL...

Gastrointestinal diseases are among the most inconvenient types of illnesses to have, and not just because they may have you running to the loo every five minutes. The field covers many diseases like Irritable Bowel Syndrome (IBS), Crohn’s...

Microbiome company Immuron (ASX: IMC) has posted a six-monthly unaudited gross revenue of $1.68 million for worldwide sales of its over-the-counter gastrointestinal and digestive health supplement Travelan. The company recorded robust gross...

You don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the most complicated mysteries still to be solved today: the human body. Biotech CEOs and chairs tend to be the cross-over scientists. However,...

Cancer is a crowded market, pot has sleep and pain issues covered — or so they say — and companies dip in and out of respiratory diseases all the time. But there are a few ASX-listed stocks that are tackling health issues that still rate as...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Investing in Small-Cap Stocks Biotech is a dynamic and profitable sector for investors. Capital venture in biotech stocks provides great enthusiasm and diversification support to market fans. In general, before investing money in stocks, in...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

What's hot Immuron Limited (ASX:IMC) Immuron closed up 66% to finish at 17.5c on $3.69 million stock traded. The reason for the rise was a new research agreement with the Naval Medical Research Centre (NMRC), Silver Spring, MD, USA. AU$5.5...

On Stockhead today: are semiconductors about to pick up again, California’s first pot cafe opens, biotech losers’ remarkable comeback, and angel investment firm Investible closes with $22m round. But first:   The day ahead Today the Austral...

It is not often that headlines on the ASX really stand out. Aside from the obvious mining hits, tech partnerships and biotech results, most of the announcements released via the ASX’s platform each day read “daily share buyback notice”, “ap...

Microbiome company Immuron (ASX: IMC), a firm that specialises in developing oral immunotherapeutic treatments for gut mediated diseases, has struck a $5.5 million deal with the US Department of Defense to engineer an effective therapeutic...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Immuron Ltd (ASX:IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens released extremely promising clinical r...

Shares in biotech Orthocell (ASX:OCC) are on the move again today after the company reported further positive results for its CelGro technology. Patients who completed the company’s CelGro tendon regeneration trial reported they had regaine...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

In delivering its annual report on Friday, Immuron Ltd (ASX:IMC) provided a promising update in relation to its various activities in the health and biotech sectors. The group's principal activity is oral immunotherapy research and developm...

On 15 August 2019, the S&P/ASX 200 Health Care Index is down 2.48% to 34,883, while the benchmark index S&P/ASX 200 was down by 2.65% and trading at 6,425.5 (as at AEST: 2:08 PM). In this article, we will discuss four stocks that ar...

Shares in Immuron took a 17 per cent hit this morning after the company revealed its IMM-124E drug did not work in a trial with patients suffering from severe alcoholic hepatitis. Immuron (ASX:IMM), which is developing oral drugs for gut di...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...

Australian biopharmaceutical company,Immuron Limited (ASX: IMC), headquartered in Carlton, is engaged in developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectiou...

Immuron (ASX:IMC), an Australian biopharmaceutical company focused on developing and commercialising oral immunoglobulin therapeutics for the treatment of gut mediated diseases, has announced the pricing of an underwritten public of...

Even though the stock markets are sensitive to the global macro-economic parameters, in the present scenario, the investors need to maintain their focus towards the US corporate earnings. The companies, generally, provide information on how...

Healthcare Healthcare sector comprises of the companies that offer medical services, producing medical equipment or medicines. These companies also give medical insurance to the patients. In Australia, the funding of healthcare is taken ca...

Aussie biopharmaceutical company Immuron Limited [ASX:IMC] is thriving in the early hours of today’s trading. Within the first hour after market open, Immuron shares were up a whopping 26%, to sit at 14.5 cents a share The post Immuron Shar...

Immuron (ASX: IMC) has revealed its full year 2019 revenue in North America had grown more than 50% to reach $1.16 million – driven by its Travelan gastrointestinal and digestive prophylactic health supplement to prevent traveller’s diarrhe...

In this week’s recap of substantial holders, a Dubai executive bought into Prospect Resources (ASX: PSC), Salt Funds Management sold $8.3 million of Monash IVF (ASX: MVF) and a tin company raised $20 million to save itself from the ‘three-y...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...

Australian biopharmaceutical group, Immuron Ltd (ASX:IMC; NASDQ:IMRN), has provided an extremely promising update on the company’s cooperative research and development agreements with the US Department of Defence, no doubt contributing to i...

Australian biopharmaceutical company Immuron (ASX: IMC) has reported positive results from a study designed to test the efficacy of Travelan anti-dysentery medication on non-human primates. The placebo-controlled Shigellosis challenge study...

Immuron Limited (ASX:IMC | NASDAQ:IMRN) has provided a steady stream of positive news across its microbiome immunotherapy platform — which includes assets that are preclinical, at clinical stage, and the already on-the-market Travelan® prod...

Immuron Limited (ASX:IMC | NASDAQ:IMRN) is focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.